Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDER’s Office Of Pharmaceutical Quality Remains A Wild Card

Executive Summary

Few details have been released about proposed new office that was part of the reason the Office of Generic Drugs director resigned.

Advertisement

Related Content

US FDA's Patient Affairs Office Is An Office … In Spirit
FDA Generics Director’s Departure Shows Why Chemistry Matters
Paging Dr. McClellan: FDA Calls On Brookings For PDUFA Research
Buying Time: Industry Sacrifices Early To Gain Later With PDUFA V Review Model
Generic Drugs Gain Status Boost Within CDER

Topics

Advertisement
UsernamePublicRestriction

Register

PS055189

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel